Clementia Pharmaceuticals Inc.

This study is testing whether an oral medication called fidrisertib can slow the formation of new, abnormal bone in people with Fibrodysplasia Ossificans Progressiva (FOP), a rare and severely disabling genetic disease. Researchers will compare two different doses of the drug aga…